BioSpace News Archive

BridGene Biosciences, Inc. announced that it will present a poster, titled “Preclinical characterization of BGI-9004, a covalent TEAD inhibitor with exceptional anti-cancer activity and combination potential,” at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 18 in Orlando.

Xyall and Indica Labs have entered into a global strategic partnership designed to bridge the gap between histology and molecular pathology.

Presage Biosciences will present at the Immunology, TME Minisymposium at the American Association for Cancer Research (AACR) 2023 Annual Meeting.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 22nd Annual Needham Virtual Healthcare Conference held on April 19, 2023. Mr. Patel will also be hosting a fireside chat at 11:45 AM Eastern Time.

Ventus Therapeutics, Inc. announced the details of two presentations to be made at the Keystone Symposium on Innate Immunity: From Innate Sensing to Adaptive Responses, being held April 16-19 in Snowbird, Utah.

GE HealthCare (Nasdaq: GEHC), a leader in health technology, will showcase its growing portfolio of digital platforms and solutions at the Health Information and Management Systems Society, Inc. (HIMSS) Global Health Conference and Exhibition in Chicago from April 17-21, 2023.

Standard BioTools Inc. today announced the launch of its newest imaging technology, the Hyperion XTi™ Imaging System, during the American Association for Cancer Research (AACR) meeting in Orlando.

In support of global initiatives to advance molecular profiling in oncology, Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant and the opening of its submissions for Spring 2023.

Veracyte, Inc. announced that new data published in European Urology Oncology suggest the Decipher Prostate Genomic Classifier could help identify prostate cancer patients who have micrometastatic disease and who may therefore benefit from systemic treatment intensification.

OSI Systems, Inc. (Nasdaq: OSIS) today announced that it will hold its quarterly conference call on Thursday, April 27, 2023 at 9:00am PT to discuss its results for the quarter ended March 31, 2023.